POP Biotechnologies
POP Biotechnologies is dedicated to advancing medical breakthroughs through innovative nanotechnology solutions, focusing on oncology and infectious disease. Their proprietary SNAP technology enables rapid vaccine development and targeted therapies, aiming to transform treatment approaches in these critical areas.
Industries
N/A
Nr. of Employees
small (1-50)
POP Biotechnologies
1576 Sweet Home Road, Suite 221, Buffalo, NY 14228
Patents
Vaccine composition for chickenpox or Varicella Zoster and method of using same
US-12527859-B2
View Details
Vaccine composition for chickenpox or Varicella Zoster and method of using same
US-12527859-B2
View DetailsProducts
Nanoliposome vaccine platform (His-tag antigen insertion)
A liposome-based platform that stably displays His-tagged proteins and peptides on lipid bilayers to create multivalent particulate vaccines with integrated adjuvants.
Light-activated liposomal chemotherapy formulation (phototriggered release)
Porphyrin-containing liposomal formulation designed to enhance tumor drug deposition and enable localized release of encapsulated chemotherapeutics when activated by red light.
Nanoliposome vaccine platform (His-tag antigen insertion)
A liposome-based platform that stably displays His-tagged proteins and peptides on lipid bilayers to create multivalent particulate vaccines with integrated adjuvants.
Light-activated liposomal chemotherapy formulation (phototriggered release)
Porphyrin-containing liposomal formulation designed to enhance tumor drug deposition and enable localized release of encapsulated chemotherapeutics when activated by red light.
Services
Partnerships for rapid vaccine candidate generation, joint preclinical testing, and support for clinical translation using antigen-displaying liposomes and integrated adjuvants.
Contract-scale manufacture of key porphyrin-phospholipid components for vaccine and therapeutic formulations at a reported 2.5M dose production scale under GMP.
Provision or coordination of GLP toxicology studies and in vivo efficacy testing to support regulatory submissions.
Partnerships for rapid vaccine candidate generation, joint preclinical testing, and support for clinical translation using antigen-displaying liposomes and integrated adjuvants.
Contract-scale manufacture of key porphyrin-phospholipid components for vaccine and therapeutic formulations at a reported 2.5M dose production scale under GMP.
Provision or coordination of GLP toxicology studies and in vivo efficacy testing to support regulatory submissions.
Expertise Areas
- Vaccine platform development
- Nanoparticle drug delivery
- Phototriggered therapeutics and photodynamic augmentation
- Preclinical and clinical development (Phase I–III support)
Key Technologies
- Liposome-based antigen display
- His-tag mediated antigen insertion
- Porphyrin-phospholipid nanovesicles
- Photodynamic activation / light-triggered release
News & Updates
Positive results for a pentavalent peptide vaccine targeting Alzheimer’s Disease, demonstrating efficacy in mice and advancing toward clinical trials.
Collaboration with FunPep for advanced preclinical testing of antibody-inducing peptides.
Commencement of dosing for the shingles vaccine 'EuHZV' in collaboration with EuBiologics in a Phase 1 clinical study in Korea.
Positive results for a pentavalent peptide vaccine targeting Alzheimer’s Disease, demonstrating efficacy in mice and advancing toward clinical trials.
Collaboration with FunPep for advanced preclinical testing of antibody-inducing peptides.
Commencement of dosing for the shingles vaccine 'EuHZV' in collaboration with EuBiologics in a Phase 1 clinical study in Korea.